| ... |
|
elixhauser-aids-vs.edn
|
616 B |
|
elixhauser-alcohol-abuse-vs.edn
|
639 B |
|
elixhauser-blood-loss-anemia-vs.edn
|
651 B |
|
elixhauser-cancer-leukemia-vs.edn
|
638 B |
|
elixhauser-cancer-lymphoma-vs.edn
|
638 B |
|
elixhauser-cancer-metastatic-vs.edn
|
651 B |
|
elixhauser-cancer-solid-tumor-in-situ-vs.edn
|
682 B |
|
elixhauser-cancer-solid-tumor-malignant-vs.edn
|
697 B |
|
elixhauser-cerebrovascular-disease-vs.edn
|
669 B |
|
elixhauser-chronic-pulmonary-disease-vs.edn
|
675 B |
|
elixhauser-coagulation-deficiency-vs.edn
|
666 B |
|
elixhauser-congestive-heart-failure-vs.edn
|
670 B |
|
elixhauser-deficiency-anemia-vs.edn
|
651 B |
|
elixhauser-dementia-vs.edn
|
624 B |
|
elixhauser-depression-vs.edn
|
630 B |
|
elixhauser-diabetes-complicated-vs.edn
|
675 B |
|
elixhauser-diabetes-uncomplicated-vs.edn
|
682 B |
|
elixhauser-drug-abuse-vs.edn
|
630 B |
|
elixhauser-hypertension-complicated-vs.edn
|
673 B |
|
elixhauser-hypertension-uncomplicated-vs.edn
|
679 B |
|
elixhauser-hypothyroidism-vs.edn
|
642 B |
|
elixhauser-liver-disease-mild-vs.edn
|
654 B |
|
elixhauser-liver-disease-severe-vs.edn
|
672 B |
|
elixhauser-neurological-movement-disorder-vs.edn
|
691 B |
|
elixhauser-neurological-seizure-disorder-vs.edn
|
688 B |
|
elixhauser-obesity-vs.edn
|
621 B |
|
elixhauser-other-neurological-vs.edn
|
664 B |
|
elixhauser-other-thyroid-disorder-vs.edn
|
666 B |
|
elixhauser-paralysis-vs.edn
|
627 B |
|
elixhauser-peripheral-vascular-disease-vs.edn
|
681 B |
|
elixhauser-psychosis-vs.edn
|
627 B |
|
elixhauser-pulmonary-circulation-disorder-vs.edn
|
691 B |
|
elixhauser-renal-failure-moderate-vs.edn
|
666 B |
|
elixhauser-renal-failure-severe-vs.edn
|
660 B |
|
elixhauser-rheumatoid-arthritis-vs.edn
|
691 B |
|
elixhauser-ulcer-vs.edn
|
638 B |
|
elixhauser-valvular-disease-vs.edn
|
648 B |
|
elixhauser-weight-loss-vs.edn
|
633 B |
|
mcode-benign-uncertain-neoplasm-brain-cns-disorder-vs.edn
|
778 B |
|
mcode-body-location-and-laterality-qualifier-vs.edn
|
628 B |
|
mcode-body-location-qualifier-vs.edn
|
627 B |
|
mcode-brachytherapy-high-dose-rate-electronic-technique-vs.edn
|
577 B |
|
mcode-brachytherapy-high-dose-rate-technique-vs.edn
|
544 B |
|
mcode-brachytherapy-low-dose-rate-temporary-technique-vs.edn
|
594 B |
|
mcode-brachytherapy-modality-vs.edn
|
512 B |
|
mcode-brachytherapy-permanent-seeds-technique-vs.edn
|
571 B |
|
mcode-brachytherapy-pulsed-dose-rate-technique-vs.edn
|
550 B |
|
mcode-brachytherapy-radiopharmaceutical-technique-vs.edn
|
559 B |
|
mcode-brachytherapy-technique-vs.edn
|
546 B |
|
mcode-cancer-body-location-vs.edn
|
1.16 KB |
|
mcode-cancer-disease-status-evidence-type-vs.edn
|
563 B |
|
mcode-cancer-disorder-vs.edn
|
1.16 KB |
|
mcode-cancer-related-surgical-procedure-vs.edn
|
989 B |
|
mcode-cancer-stage-group-vs.edn
|
624 B |
|
mcode-cancer-staging-system-vs.edn
|
478 B |
|
mcode-carcinoma-in-situ-disorder-vs.edn
|
667 B |
|
mcode-clinvar-vs.edn
|
787 B |
|
mcode-condition-status-trend-vs.edn
|
515 B |
|
mcode-cytologic-evidence-malignancy-vs.edn
|
685 B |
|
mcode-dna-change-type-vs.edn
|
480 B |
|
mcode-genomic-molecular-consequence-vs.edn
|
555 B |
|
mcode-genomic-specimen-type-vs.edn
|
785 B |
|
mcode-hgnc-vs.edn
|
475 B |
|
mcode-hgvs-vs.edn
|
543 B |
|
mcode-histology-morphology-behavior-vs.edn
|
1.14 KB |
|
mcode-hypereosinophilic-syndrome-disorder-vs.edn
|
694 B |
|
mcode-laterality-qualifier-vs.edn
|
481 B |
|
mcode-melanoma-in-situ-disorder-vs.edn
|
664 B |
|
mcode-observation-codes-distant-metastases-vs.edn
|
578 B |
|
mcode-observation-codes-primary-tumor-vs.edn
|
563 B |
|
mcode-observation-codes-regional-nodes-vs.edn
|
565 B |
|
mcode-observation-codes-stage-group-vs.edn
|
545 B |
|
mcode-present-absent.edn
|
572 B |
|
mcode-primary-cancer-disorder-vs.edn
|
680 B |
|
mcode-primary-malignant-neoplasm-disorder-vs.edn
|
695 B |
|
mcode-procedure-intent-vs.edn
|
467 B |
|
mcode-radiotherapy-modality-vs.edn
|
667 B |
|
mcode-radiotherapy-technique-vs.edn
|
647 B |
|
mcode-radiotherapy-treatment-location-qualifier-vs.edn
|
596 B |
|
mcode-radiotherapy-treatment-location-vs.edn
|
737 B |
|
mcode-radiotherapy-volume-type-vs.edn
|
700 B |
|
mcode-secondary-cancer-disorder-vs.edn
|
686 B |
|
mcode-teleradiotherapy-carbon-ion-beam-technique-vs.edn
|
539 B |
|
mcode-teleradiotherapy-electron-beam-technique-vs.edn
|
533 B |
|
mcode-teleradiotherapy-modality-vs.edn
|
537 B |
|
mcode-teleradiotherapy-neutron-beam-technique-vs.edn
|
530 B |
|
mcode-teleradiotherapy-photon-beam-technique-vs.edn
|
527 B |
|
mcode-teleradiotherapy-proton-beam-technique-vs.edn
|
527 B |
|
mcode-teleradiotherapy-technique-vs.edn
|
539 B |
|
mcode-tnm-distant-metastases-category-vs.edn
|
653 B |
|
mcode-tnm-primary-tumor-category-vs.edn
|
643 B |
|
mcode-tnm-regional-nodes-category-vs.edn
|
645 B |
|
mcode-treatment-termination-reason-vs.edn
|
746 B |
|
mcode-tumor-marker-test-vs.edn
|
788 B |
|
mcode-tumor-size-method-vs.edn
|
539 B |
|
mcode-tumor-size-units-vs.edn
|
484 B |